Our History

A strong background in HIV:

Scientists at Theratechnologies discovered EGRIFTA® (tesamorelin for injection) in 1995. For the next fifteen years, Theratechnologies pursued the development of this innovative treatment for lipodystrophy in people living with HIV. In 2010, Theratechnologies received a marketing authorization for EGRIFTA® from the U.S. Food and Drug Administration (FDA).

EGRIFTA® was first marketed in the U.S. by a third-party commercial partner. In 2014, Theratechnologies reoriented its business model to become a commercial-stage biopharmaceutical company and regained U.S. commercial rights.

In 2016, the Company concluded an agreement to acquire the commercial rights to Trogarzo® in the U.S, and other markets. Trogarzo® was approved by the FDA in 2018 and was quickly adopted by physicians to treat people living with a persistent HIV viral load.

On October 3, 2022, the FDA approved an IV push method of administration of Trogarzo®. The Company is also investigating administration by intramuscular injection.

For full prescribing information and safety information on our products please visit: www.trogarzo.com www.egriftasv.com

Discovering new pathways in oncology:

Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. TH1902, the leading product candidate derived from the SORT1+ Technology, is a first-in-class peptide-drug conjugate (PDC) that targets the sortilin receptor. In 2021, the FDA granted a Fast-Track Designation to TH1902 for developmentas a single agent for the treatment of patients with sortilin-positive recurrent advanced solid tumors that are refractory to standard therapy.

Promising research in NASH:

Theratechnologies is pursuing the development of tesamorelin for the treatment of nonalcoholic steatohepatitis - or NASH - in the general population. The Company continues to have discussions with potential partners with resources and capabilities for the conduct of a Phase 2b/3 study.